

## **NEUROLOGY START FORM**

C	1-833-ZEPOSIA (833-937-6742)
	1-833-727-7701
	WWW.covermymeds.com

Full name*		Date	e of birth*/ _	/ Sex* M
Address*		Phone*		OK to leave voicem
City, State, ZIP*		Email		Language
Prescription Insurance Cov	verage			
See attached copy of front	=	d(s). This section is nov	v complete.	
I do not have prescription		(-/		
Prescription insurance carrier				
Rx Member ID*		Rx Group ID		
Rx PCN (if applicable)		Rx BIN (if appl	licable)	
Please continue to the Pati	ent Authorization and			
and a copy of the patient's many belief blank if baseline patient has been or will be cleared for the Assistance requested to colf requesting assistance, a Baseline Asses Blood tests:	assistance is not being requested erapy prior to initiation, and that p anduct the following at assment Clearance Form will be	. If this section is left blank, the horoduct may be shipped.  t the patient's home <sup>†</sup> ; uuired upon review and approva	ealthcare provider comp : I of the results lect patients:	oleting this form represents that t
LFTs †Eligible, commercially insured patients. F		uirements and Terms and Condi		Macular edema screenin
Diagnosis & Prescription(s)				
Primary diagnosis*				
ICD 10 G35 Multiple Sclero	sis			
Other				
*Has your patient already rec	eived ZEPOSIA? No	Yes, Initiated (MM/YY)		
Initiation Rx*	Bridge*‡		Maintenance R	<b>×</b> *‡
ZEPOSIA Starter Kit:	ZEPOSIA 0.92 mg caps	sule by mouth:		g capsule by mouth:
ZEI OON (Otal tel 14tt.		Once every other days		or Once every other d
one capsule by mouth		, ,		
as directed per package	30-day supply folloy	ved by II refills	30-day supply	v tollowed by II retills
as directed per package titration instructions	30-day supply follow	ved by II refills		y followed by 11 refills
as directed per package	ole for eligible patients. Please see a	additional eligibility requirements	90-day suppl	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills) *Free Trial Offer and Bridge options available	ole for eligible patients. Please see a patients with mild or moderate chro	additional eligibility requirements	90-day suppl	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills) *Free Trial Offer and Bridge options available *Recommended maintenance dosage in p	ole for eligible patients. Please see a patients with mild or moderate chro	additional eligibility requirements	90-day suppl	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills)  Free Trial Offer and Bridge options availate Recommended maintenance dosage in preferred specialty pharmacy Additional notes:	ole for eligible patients. Please see a patients with mild or moderate chro	additional eligibility requirements	90-day suppl	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills)  *Free Trial Offer and Bridge options availab *Recommended maintenance dosage in p Preferred specialty pharmacy Additional notes:  Prescriber Information	ole for eligible patients. Please see a patients with mild or moderate chro	additional eligibility requirements	90-day suppl	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills)  *Free Trial Offer and Bridge options availat *Recommended maintenance dosage in p Preferred specialty pharmacy Additional notes:  Prescriber Information Full name*	ole for eligible patients. Please see a patients with mild or moderate chro	ndditional eligibility requirements onic hepatic impairment (Child-P	90-day suppl and Terms and Condition rugh class A or B) is 0.92 n	y followed by 3 refills
as directed per package titration instructions (1 kit, 0 refills)  *Free Trial Offer and Bridge options available secommended maintenance dosage in package preferred specialty pharmacy	ole for eligible patients. Please see a patients with mild or moderate chro	ndditional eligibility requirements onic hepatic impairment (Child-F	90-day suppl and Terms and Condition rugh class A or B) is 0.92 n	y followed by 3 refills ns on page 4. ng once every other day.  Ext.
as directed per package titration instructions (1 kit, 0 refills)  *Free Trial Offer and Bridge options availate *Recommended maintenance dosage in perferred specialty pharmacy Additional notes:  Prescriber Information Full name* Address*	Office  A based on my professional judgmormation to BMS and its respective if required by HIPAA or other appliany free product provided to the plispensing pharmacy. I understances activities.	NPI #*  Pho  The contact  Photo  Phot	90-day suppl and Terms and Condition ugh class A or B) is 0.92 m  Fax*  one*  Ema  It I will supervise the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided is accurately support to transmit provided in the paticulation provided in the paticulation provided is accurately support to transmit provided in the paticulation provide	y followed by 3 refills ns on page 4. ng once every other day.  Ext.  iii  Ext.  ent's medical treatment; (2) I have obtarmacy, and I have obtained this te to the best of my knowledge; prescription(s) below by any mean

# NEUROLOGY START FORM

1-833-ZEPOSIA (833-937-6742)1-833-727-7701

www.covermymeds.com

### PATIENT AUTHORIZATION AND AGREEMENT

Bristol-Myers Squibb Company ZEPOSIA 360 Support™ is a support program by Bristol-Myers Squibb Company (BMS) that helps patients understand their insurance coverage and financial support options for ZEPOSIA® (ozanimod), as well as educational, nurse, lab, and diagnostic support services and free medication to qualified patients (the "Program"). To participate in the Program, BMS will need to receive, use, and disclose your personal information. You also have the option to participate in the ZEPOSIA 360 Support Co-pay Assistance Program by separately enrolling below. Please read this authorization carefully, and contact ZEPOSIA 360 Support at 1-833-ZEPOSIA (833-937-6742) if you have any questions. Once you have read and agreed to this form, fax your signed copy to 833-727-7701.

- 1. What information will be used and disclosed? My personal information will be disclosed, including: The information on the Program enrollment form; my contact information, date of birth, and phone carrier/device information (for calls and texts); professional and employment information, financial and income information, insurance information, health records and information, including diagnoses, medications, and lab tests and biometric and genetic information, including tests that identify the kind of illness that I have and/or medication indicated for my treatment.
- 2. Who will disclose, receive, and use the information? This authorization permits my health caretakers, which include my healthcare providers, pharmacies, lab service providers, diagnostic service providers, health plans, and health insurers who provide services to me, as well as other people who I say can help me apply, to disclose my personal information to BMS, the third parties it works with, and other authorized agents, subsidiaries, and assignees (collectively "BMS"). BMS may also share my information with my health caretakers and with other healthcare providers, pharmacists, health insurers, and charitable organizations to determine if I am eligible for, or enrolled in, another plan or program.
- **3. What is the purpose for the use and disclosure?**My personal information will be used by and shared with the persons and organizations described in this authorization in order to:
  - Process my application for the Program and provide services to me, including verifying my insurance benefits, assistance with prior authorizations from my insurance, researching alternative insurance coverage options, providing information and education about the services through a case manager, and referring me and my health caretakers to other plans, support, or assistance programs that may be able to help me with access to my medication, including screenings for other financial assistance options such as medication co-pay assistance
  - Provide me with healthcare services, including lab and diagnostic tests and related healthcare procedures related to ZEPOSIA. I understand these healthcare services are

- not provided, or employed, by my healthcare professional. I understand that my insurance may be billed for these services and that I may have a separate co-pay or cost-sharing obligation for using these services
- Provide free medication to me, if I am eligible
- Receive and/or purchase my information (including information about my prescriptions and insurance claims) from my health caretakers to determine if and where I am receiving my medication and whether I am no longer eligible for free medication or other BMS support programs
- Contact my health caretakers and me about the programs and the services that are available
- Contact other healthcare providers and charitable organizations to determine if I am eligible for, or enrolled in, another plan or program
- Contact me for marketing purposes, including providing me with information about my medication, refill reminders, surveys, and other information and alerts that BMS believes may be of interest to me (and some of which may be sent directly to my phone if I choose)
- Improve or develop the Program's services and other internal business purposes, including analytics
- BMS also may use my health information to combine it with other information BMS may collect about me and my ZEPOSIA treatment and use it for the purposes described above

Authorization for Sale of My Information to BMS: I authorize my health caretakers (including my healthcare providers, health plans, health insurers, pharmacies, lab service providers, and diagnostic service providers) to disclose my information for the purposes described in this authorization, and I further authorize my health caretakers to accept payment from BMS in exchange for providing my information as well as providing me with marketing and patient support services.

- 4. When will this authorization expire? This authorization will be effective for 5 years unless it expires earlier by law or I cancel it in writing. I may cancel this authorization by writing to: ZEPOSIA 360 Support, PO Box 310, Columbus, OH 43216. If I cancel this authorization, I will no longer be able to participate in the Program. The Program will stop using or disclosing my information for the purposes listed in this authorization, except as necessary to end my participation or as required or allowed by law. I understand that if I receive free medication, I must re-apply at least every year, sign this authorization again, and be accepted.
- **5. Notices:** I understand that once my health information has been disclosed, privacy laws may no longer restrict its use, disclosure, or further re-disclosures. BMS may use and disclose my information for the purposes described in this authorization or as allowed or required by law. I understand that BMS does not sell or rent personal information collected about me from this Program. I have a right to receive a copy of this

# NEUROLOGY START FORM

1-833-ZEPOSIA (833-937-6742)□ 1-833-727-7701

www.covermymeds.com

### PATIENT AUTHORIZATION AND AGREEMENT

authorization after I have signed it. I further understand that I may refuse to sign this authorization and that if I refuse, my eligibility for health plan benefits and treatment by my healthcare providers will not change, but I will not have access to the Program services. I understand that certain state laws may allow for the right to request access to, or deletion of, my information. I understand that these state rights are not absolute and only apply in certain circumstances. Therefore, I acknowledge that I may not receive a response to my request to the extent required or permitted under relevant

laws. I agree that I may need to provide additional information in order to verify my identity, such as a government-issued ID, before my request to receive access to, or deletion of, my information will be honored. I will not be discriminated against for exercising my rights, but I understand that I may not be able to receive Program services if I do not allow use of my information. To submit an access or deletion request, I may call 1-833-ZEPOSIA (833-937-6742) or complete the online form at www.bms.com/dpo/us/request.

Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for a cinformation, BMS may delay or terminate participation. Additional terms apply for co-pay assistance and free medication. BMS may delay or terminate participation additional terms apply for co-pay assistance and free medication. BMS may discontinue the Program the rules for participation at any time, without any notice.  The patient or his/her legal representative must be provided with a copy of both pages of the Patient Authorization and Agreement Form after it has bee Power of Attorney documentation is required if someone other than the patient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for frassistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand that authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. Lost pout autodialed calls and text messages are valid with mo US carriers. In understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program un	Therefore, I acknowledge that I may not receive a my request to the extent required or permitted un	response to the online form	at www.bms.com/dp	,
Signature of patient or legal representative*  Full name of patient or legal representative  Date (MM. Date of birth*   /   /   Relationship  Email  Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for an information ability of the patient's personal information in the true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information if there is missing information or the patient does not respond to requests for an information is patient to ship the patient of	I have read the Patient Authorization and A	reement and agree to its te		
Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for a cinformation, BMS may delay or terminate participation, Additional terms apply for co-pay assistance and free medication. BMS may discontinue the Program the rules for participation at any time, without any notice.  The patient or his/her legal representative must be provided with a copy of both pages of the Patient Authorization and Agreement Form after it has bee Power of Attorney documentation is required if someone other than the patient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for frassistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of automated texts and calls.  Consent for autodialed calls and text (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand that authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that try carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used and used by the Program under the terms of this authorization. Lost populations are also and text messages and call and text messages are valid with more acceptance of the program and connection of the program	Prefer to authorize your consent online? Visi	ZEPOSIA.COM/ESIGN to sub	omit your signature	electronical
Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for a cinformation, BMS may delay or terminate participation, Additional terms apply for co-pay assistance and free medication. BMS may discontinue the Program the rules for participation at any time, without any notice.  The patient or his/her legal representative must be provided with a copy of both pages of the Patient Authorization and Agreement Form after it has bee Power of Attorney documentation is required if someone other than the patient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for frassistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of automated texts and calls.  Consent for autodialed calls and text (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand that authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that try carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used and used by the Program under the terms of this authorization. Lost populations are also and text messages and call and text messages are valid with more acceptance of the program and connection of the program				
Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for as information, BMS may delay or terminate participation. Additional terms apply for co-pay assistance and free medication. BMS may discontinue the Program of the rules for participation at any time, without any notice.  The patient or his/her legal representative must be provided with a copy of both pages of the Patient Authorization and Agreement Form after it has bee Power of Attorney documentation is required if someone other than the patient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for for assistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand that authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages at any time calling ZEPOSIA 360 Support™ at 1-833-ZEPOSIA (833-937-67/42). I can also stop text messages by texting "STOP" to the phone number from which I received a text message.  ZEPOSIA 360 CO-PAY ASSISTANCE PROGRAM  If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program is a support program that provides	Signature of patient or legal representative <sup>†</sup>	Full name of patient or lega	al representative	Date (MM/
Program Terms: In order to provide Access Assistance, patients must provide information that is true and complete. At any time during participation, BMS may design and complete additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for a information, BMS may delay or terminate participation. Additional terms apply for co-pay assistance and from the patient does not respond to requests for a chiral representation of the patient of the patient and the patient of the	Date of birth* / / Relationship			
request additional documentation to verify the patient's personal information. If there is missing information or the patient does not respond to requests for acinformation, BMS may delay or terminate participation. Additional terms apply for co-pay assistance and free medication. BMS may discontinue the Program of the rules for participation at any time, without any notice.  The patient or his/her legal representative must be provided with a copy of both pages of the Patient Authorization and Agreement Form after it has bee Power of Attorney documentation is required if someone other than the patient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for for assistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand the authorization is not a condition of purchase, or use, of ZEPOSIA" (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages and text messages.  ZEPOSIA 360 Support™ at 1-833-32FOSIA (833-937-6742), I can also stop text messages by texting "STOP" to the phone number from which I received a text message.  ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other patie support information for ZEPOSIA and r	Email			
Power of Attorney documentation is required if someone other than the jatient signs. You may fax the documents to 1-833-727-7701 or call 1-833-937-6742 for frassistance. NOTE: Enrollment cannot be processed without a valid signature.  Yes, I consent to receive text messages. I have read the Terms and Conditions and agreed to receive text messages and calls as explained in the consent for automated texts and calls.  Consent for autodialed calls and texts (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand tha authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages at any time calling ZEPOSIA 360 Support™ at 1-833-ZEPOSIA (833-937-6742). I can also stop text messages by texting "STOP" to the phone number from which I received a text message.  ZEPOSIA 360 CO-PAY ASSISTANCE PROGRAM  If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program. I have read the co-pay terms and conditions (pg 4) and agree to its term. The ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me acreaivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to combact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical train other information of first that it b	request additional documentation to verify the patient's personal in information, BMS may delay or terminate participation. Additional t	ormation. If there is missing information or	r the patient does not respond	d to requests for add
Consent for autodialed calls and texts (optional): I authorize the receipt of autodialed calls and text messages from BMS and the Program. I understand the authorization is not a condition of purchase, or use, of ZEPOSIA* (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages at any tim calling ZEPOSIA 360 Support" at 1-833-ZEPOSIA (833-937-6742). I can also stop text messages by texting "STOP" to the phone number from which I received text message. For help, I can text "HELP" to the phone number from which I received a text message.  ZEPOSIA 360 CO-PAY ASSISTANCE PROGRAM  If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program. I have read the co-pay terms and conditions (pg 4) and agree to its terr. The ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of the support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me a caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to combine it with a other information and offers	Power of Attorney documentation is required if someone other than	the patient signs. You may fax the docume		
authorization is not a condition of purchase, or use, of ZEPOSIA® (ozanimod) or any other BMS products and that the Program's services are valid with mo US carriers. I understand that my carrier's message and data rates may apply. I understand that information BMS obtains from me in connection with use autodialed calls and text messages is used by the Program under the terms of this authorization. I can stop autodialed calls and text messages at any time calling ZEPOSIA 360 Support™ at 1-833-ZEPOSIA (833-937-6742). I can also stop text messages by texting "STOP" to the phone number from which I received text message. For help, I can text "HELP" to the phone number from which I received a text message.  ZEPOSIA 360 CO-PAY ASSISTANCE PROGRAM  If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program. I have read the co-pay terms and conditions (pg 4) and agree to its term. The ZEPOSIA Co-pay Assistance Program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of the support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me a caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical trial other information and offers that it believes to be of interest to me. BMS may also use my information in order to improve or develop its services and for or internal business purposes including analytics, communication services, and marketing activities. BMS also may use my information to combine it with or information BMS may collect about me and my treatment and use it for the purposes d			_	ceive text
If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program. I have read the co-pay terms and conditions (pg 4) and agree to its term. The ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of the support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical trial other information and offers that it believes to be of interest to me. BMS may also use my information in order to improve or develop its services and for ointernal business purposes including analytics, communication services, and marketing activities. BMS also may use my information to combine it with oinformation BMS may collect about me and my treatment and use it for the purposes described above. Use of my information will be governed by the BP rivacy Policy. From time to time the Privacy Policy may change and I understand that I should check the website at <a href="https://www.bms.com">www.bms.com</a> for the most recent	authorization is not a condition of purchase, or use, of ZEPOSIA® US carriers. I understand that my carrier's message and data rate autodialed calls and text messages is used by the Program undecalling ZEPOSIA 360 Support™ at 1-833-ZEPOSIA (833-937-6742)	ozanimod) or any other BMS products and s may apply. I understand that information the terms of this authorization. I can stop I can also stop text messages by texting "	d that the Program's services n BMS obtains from me in col o autodialed calls and text me	are valid with mos nnection with use essages at any time
If eligible, I would like to enroll in the ZEPOSIA Co-pay Assistance Program. I have read the co-pay terms and conditions (pg 4) and agree to its term. The ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of the support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical trial other information and offers that it believes to be of interest to me. BMS may also use my information in order to improve or develop its services and for ointernal business purposes including analytics, communication services, and marketing activities. BMS also may use my information to combine it with oinformation BMS may collect about me and my treatment and use it for the purposes described above. Use of my information will be governed by the BP rivacy Policy. From time to time the Privacy Policy may change and I understand that I should check the website at <a href="https://www.bms.com">www.bms.com</a> for the most recent				
The ZEPOSIA Co-pay Assistance Program is a support program that provides eligible patients with co-pay assistance, reminders, surveys, and other paties support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of the support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me a caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical trial other information and offers that it believes to be of interest to me. BMS may also use my information in order to improve or develop its services and for of internal business purposes including analytics, communication services, and marketing activities. BMS also may use my information to combine it with of information BMS may collect about me and my treatment and use it for the purposes described above. Use of my information will be governed by the B Privacy Policy. From time to time the Privacy Policy may change and I understand that I should check the website at <a href="https://www.bms.com">www.bms.com</a> for the most recent	ZEPOSIA 360 CO-PAY ASSISTA	NCE PROGRAM		
support information for ZEPOSIA and related disease information. I understand that the information I provide, along with information about my use of th support program services will be stored and used by Bristol Myers Squibb and parties acting on its behalf ("BMS") to provide the support services to me a caregivers/alternate contacts that are listed on this form or that I otherwise designate in writing. BMS may also store and use my information to contact my designated caregivers/alternate contacts via mail, telephone, in electronic format or otherwise about products, services, market research, clinical trial other information and offers that it believes to be of interest to me. BMS may also use my information in order to improve or develop its services and for of internal business purposes including analytics, communication services, and marketing activities. BMS also may use my information to combine it with of information BMS may collect about me and my treatment and use it for the purposes described above. Use of my information will be governed by the BI Privacy Policy. From time to time the Privacy Policy may change and I understand that I should check the website at <a href="https://www.bms.com">www.bms.com</a> for the most recent	If eligible, I would like to enroll in the ZEPOSIA Co-pay Assista	nce Program. I have read the co-pay terr	ns and conditions (pg 4) an	d agree to its term
	support information for ZEPOSIA and related disease informatic support program services will be stored and used by Bristol Mye caregivers/alternate contacts that are listed on this form or that my designated caregivers/alternate contacts via mail, telephone of the information and offers that it believes to be of interest to ninternal business purposes including analytics, communication information BMS may collect about me and my treatment and up to the suppose of the	n. I understand that the information I proves Squibb and parties acting on its behalf otherwise designate in writing. BMS may in electronic format or otherwise about pee. BMS may also use my information in or ervices, and marketing activities. BMS also it for the purposes described above. Us	vide, along with information a ("BMS") to provide the suppo also store and use my inform products, services, market res der to improve or develop its so may use my information to se of my information will be ge	about my use of the ort services to me an action to contact m search, clinical trials services and for ot o combine it with of overned by the BM
I can stop future marketing communications and use of my information by calling 1-833-ZEPOSIA (833-937-6742).	Privacy Policy. From time to time the Privacy Policy may change	and I understand that I should check the	website at <u>www.bms.com</u> for	



Scan this code to add our number to your phone, that way you'll always know when it's **ZEPOSIA 360 Support**™ calling. To do it manually, create a new "**ZEPOSIA 360 Support**" contact on your phone with this number: 1-833-ZEPOSIA (833-937-6742).

Full name of patient or legal representative

Signature of patient or legal representative

Date (MM/DD/YY)



# NEUROLOGY START FORM

To receive co-pay assistance or free medication from BMS, patients must comply with the Program rules and they may not be reimbursed for the assistance patients received from anyone else, including from an insurance program, another charity, or from a health savings, flexible spending, or other health reimbursement account. Assistance may be temporary and patients may be required to apply every year. Patients must contact the Program at 1-833-937-6742 if their insurance or treatment changes in any way. Medicare Part D patients may not count any free medication received toward their true out-of-pocket (TrOOP) costs.

#### **SCREENING ASSISTANCE FOR ASSESSMENTS**

Available for on-label commercially insured patients only. This offer is not valid for medical screenings for which payment may be made in whole or in part under federal or state health programs, including but not limited to Medicare or Medicaid, and for residents in RI. This program is subject to termination or modification at any time.

#### **ZEPOSIA INITIATION RX (FREE TRIAL OFFER)**

Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be new to therapy and have not previously received a sample or filled a prescription for ZEPOSIA. Patient is responsible for applicable taxes, if any. This offer is limited to one use per patient per lifetime and is non-transferable. Cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions permitted. Patients, pharmacists, and prescribers cannot seek reimbursement for the ZEPOSIA Free Trial from health insurance or any third party, including state or federally funded programs. Patients may not count the ZEPOSIA Free Trial as an expense incurred for purposes of determining out-of-pocket costs for any plan, including Medicare Part D true out-of-pocket costs (TrOOP). Offer is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law or restricted. The program is not insurance. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this offer at any time without notice.

### **BRIDGE PROGRAM**

The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPVA, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Offer is not health insurance. Once coverage is approved by the patient's commercial insurance plan, the patient will no longer be eligible. Void where prohibited by law, taxed, or restricted. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.

#### ZEPOSIA 360 CO-PAY ASSISTANCE PROGRAM

- ZEPOSIA Co-pay Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs and a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam where the full cost is not covered by patient's insurance.
- Patients are not eligible for the prescription benefit offer if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPVA, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs.
- Patients are not eligible for the medical assessment benefit offer if they have insurance coverage for their prescription or medical assessment through a state or federal healthcare program, or reside in Massachusetts, Minnesota, or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible.
- Patients must be 18 years of age or older.
- Eligible patients with an activated co-pay card and a valid prescription may pay as little as \$0 per 30-day supply; monthly, annual, and/or per-claim maximum program benefits may apply and vary from patient to patient, depending on the terms of a patient's prescription drug plan and to ensure that the funds are used for the benefit of the patient, based on factors determined solely by Bristol-Myers Squibb. Some prescription drug plans have established programs referred to as "co-pay maximizer" programs. A co-pay maximizer program is one in which the amount of the patient's out-of-pocket costs is adjusted to reflect the availability of support offered by a co-pay support program. Patients enrolled in co-pay maximizer programs may receive program benefits that vary over time to ensure the program funds are used for the benefit of the patient. Patients will be evaluated for ongoing eligibility in the prescription copay program to continue enrollment in the program. In the event patients experience a change in insurance coverage or BMS makes changes to the copay assistance program, patients may be required to re-enroll into the program and provide updated insurance information to determine eligibility. Eligible commercially insured patients may pay as little as \$0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of \$2,000. The medical benefit offer only applies to clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amounts.
- To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made.
- All Program payments are for the benefit of the patient only.
- Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription or medical assessment benefit received by the patient through this Program.
- Patient's acceptance of any Program benefit confirms that it is consistent with patient's insurance and that patient will report the value received as may be required by his/her insurance provider.
- Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted.
- The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills.
- The Program is not insurance. Other limitations may apply.
- Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.